Compare TSLX & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSLX | ZLAB |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.6B |
| IPO Year | 2011 | 2017 |
| Metric | TSLX | ZLAB |
|---|---|---|
| Price | $17.89 | $24.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $21.61 | ★ $49.60 |
| AVG Volume (30 Days) | 361.1K | ★ 923.4K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 10.82% | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ 0.15 | N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | N/A | $9.75 |
| Revenue Next Year | $1.20 | $26.03 |
| P/E Ratio | $119.07 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $16.04 | $15.96 |
| 52 Week High | $23.65 | $34.72 |
| Indicator | TSLX | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.96 | 51.52 |
| Support Level | $17.20 | $16.84 |
| Resistance Level | $17.99 | $25.28 |
| Average True Range (ATR) | 0.35 | 0.79 |
| MACD | -0.12 | -0.42 |
| Stochastic Oscillator | 13.90 | 30.05 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.